Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pembrolizumab biosimilar by Sandoz Group for Melanoma: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Sandoz Group and currently in Phase III for Melanoma. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Sandoz Group's Aflibercept Biosimilar?
Aflibercept Biosimilar is a fusion protein commercialized by Sandoz Group, with a leading Phase III program in Wet (Neovascular /...
Denosumab biosimilar by Sandoz Group for Bone Metastasis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Phase III for Bone Metastasis. According to GlobalData,...
Denosumab biosimilar by Sandoz Group for Giant Cell Tumor Of Bone: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Phase III for Giant Cell Tumor Of Bone....
Denosumab biosimilar by Sandoz Group for Humoral Hypercalcemia of Malignancy: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Humoral Hypercalcemia of Malignancy. According to...
Denosumab biosimilar by Sandoz Group for Post Menopausal Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Post Menopausal Osteoporosis. According to GlobalData,...